How Epic Bio is leveraging CRISPR without cutting DNA

What It Covers

Stanford bioengineering professor Stanley Qi, founder of EpicBio, explains how the company's GEMS platform uses a miniaturized Cas protein — one-third the size of Cas9 — to perform reversible epigenetic editing without cutting DNA, with lead program EPI-321 targeting FSHD muscular dystrophy in an upcoming Phase 1 trial.

Key Questions Answered

• •Mutation-agnostic targeting: Epigenetic editing can treat diseases with hundreds of distinct mutations in a single gene — like cystic fibrosis, which has over 2,000 mutations — using one therapeutic modality. Rather than developing separate drugs per mutation variant, a single epigenetic silencing or activation approach targets a common genomic region, bypassing the commercial and clinical feasibility barriers of ultra-rare mutation subgroups.
• •Reversibility as a safety mechanism: Unlike permanent DNA sequence edits, epigenetic modifications can be written and erased because natural cellular machinery includes both writer and eraser enzymes for marks like methylation. This built-in reversibility reduces the risk of irreversible off-target edits — a key safety advantage over standard CRISPR gene editing in clinical settings where remediation options are limited.
• •Miniaturized Cas protein enables single-vector delivery: EpicBio's proprietary CasMini protein is one-third the size of Cas9, small enough to fit an entire GEMS therapeutic — guide RNA plus epigenetic enzyme fusion — into a single AAV vector. This single-vector delivery is critical for in vivo gene therapy, where payload size constraints have historically limited what can be packaged and delivered efficiently.
• •FSHD as a proof-of-concept disease: EPI-321 targets FSHD by re-silencing the DUX4 gene via DNA methylation installation at its promoter region. FSHD is caused by inappropriate DUX4 expression across multiple gene copies — a structure resistant to standard gene editing — making it a strategically selected first indication to validate both epigenetic silencing efficacy and safety in human Phase 1 trials.
• •Pipeline diversification across delivery modalities: Beyond AAV-delivered muscle and retinal programs, EpicBio encodes epigenetic editing molecules in mRNA packaged in lipid nanoparticles for liver disease indications — the same LNP delivery platform used in approved vaccines. This dual-modality approach (AAV for post-mitotic tissues, LNP for liver) expands addressable disease categories without requiring entirely new delivery infrastructure.